Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type Journal Article
PMID (32907612)
Authors Yeh CH, Bellon M, Wang F, Zhang H, Fu L, Nicot C
Title Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
Journal Molecular cancer
Vol 19
Issue 1
Date 2020 09 09
URL
Abstract Text Human T cell leukemia virus type 1 (HTLV-1)-associated adult T cell leukemia (ATL) has a very poor prognosis with a median survival of 8 months and a 4-year overall survival of 11% for acute ATL. Present treatment options are limited and there is no curative therapy for ATL. Ubiquitin ligase FBXW7 is commonly mutated or functionally inactivated in human cancers. Consistent with the notion that FBXW7 controls the degradation of many oncoproteins, loss of FBXW7 has been linked to increased drug resistance or sensitivity in cancer cells.In this study, we have characterized FBXW7 mutants previously identified in HTLV-I-infected ATL patient samples. TET-inducible ATL cells carrying wild type or mutated FBXW7 were analyzed for target degradation and for drug sensitivity.Our results demonstrate that mutations in FBXW7 can selectively disrupt ubiquitination and proteasome degradation of target proteins: c-MYC, cyclin E and MCL1. Both c-MYC and MYCN were highly expressed in uncultured ATL patient's samples and ATL-derived cell lines; and ATL cells demonstrated sensitivity to BET inhibitors in vitro and in vivo. High-throughput reverse phase protein array revealed BRAF as a novel target of FBXW7 and further experiments showed that mutations in FBXW7 preventing degradation of BRAF provided resistance to BET inhibitors. In contrast to R465, hot spot FBXW7 mutations at R505C retained degradation of BRAF but not NOTCH1, c-MYC, cyclin E, or MCL1. Finally, a combination therapy using BET inhibitors along with a BRAF or an ERK inhibitor prevented tumor cell resistance and growth.Our results suggest that FBXW7 status may play an important role in drug therapy resistance of cancer cells. Genetic characterization of FBXW7 may be one factor included in future personalized cancer treatment identification.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
FBXW7 H468R missense loss of function FBXW7 H468R lies within WD repeat 3 of the Fbxw7 protein (UniProt.org). H468R confers a loss of function to the Fbxw7 protein as demonstrated by an inability to induce degradation of cyclin E, c-Myc, Mcl-1, and Braf in cultured cells, and confers resistance to some BET inhibitors in cultured cells (PMID: 32907612), and results in impaired degradation of NICD in cultured cells, potentially leading to increased Notch1 signaling (PMID: 27247421). Y
FBXW7 S462P missense loss of function FBXW7 S462P lies within WD repeat 3 of the Fbxw7 protein (UniProt.org). S462P confers a loss of function to the Fbxw7 protein as demonstrated by an inability to induce degradation of cyclin E, c-Myc, Mcl-1, and Braf in cultured cells, and confers resistance to some BET inhibitors in cultured cells (PMID: 32907612), and results in impaired degradation of NICD in cultured cells, potentially leading to increased Notch1 signaling (PMID: 27247421). Y
FBXW7 W425R missense loss of function FBXW7 W425R lies within WD repeat 2 of the Fbxw7 protein (UniProt.org). W425R results in degradation of Mcl1, but confers a loss of function to the Fbxw7 protein as demonstrated by impaired degradation of cyclin E, c-Myc, and Braf in cultured cells (PMID: 32907612) and leads to dimerization with wild-type Fbxw7 in cultured cells, thereby preventing degradation of NICD and potentially resulting in increased Notch signaling (PMID: 27247421), and confers resistance to some BET inhibitors in cultured cells (PMID: 32907612). Y
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FBXW7 S462P adult T-cell leukemia sensitive JQ1 + PLX8394 Preclinical - Cell culture Actionable In a preclinical study, the combination treatment of JQ1 and PLX8394 resulted in greater decreased proliferation of adult T cell leukemia cells expressing FBXW7 S462P when compared to treatment with JQ1 alone in culture (PMID: 32907612). 32907612
Unknown unknown adult T-cell leukemia not applicable JQ1 Preclinical - Patient cell culture Actionable In a preclinical study, patient-derived adult T cell leukemia cell lines with likely activation of Myc pathway signaling demonstrated decreased proliferation when treated with JQ1 in culture (PMID: 32907612). 32907612
FBXW7 W425R adult T-cell leukemia resistant Birabresib Preclinical - Cell culture Actionable In a preclinical study, adult T cell leukemia cells expressing FBXW7 W425R demonstrated resistance to treatment with Birabresib (OTX015) in culture (PMID: 32907612). 32907612
FBXW7 S462P adult T-cell leukemia resistant Birabresib Preclinical - Cell culture Actionable In a preclinical study, adult T cell leukemia cells expressing FBXW7 S462P were resistant to treatment with Birabresib (OTX015) in culture (PMID: 32907612). 32907612
FBXW7 S462P adult T-cell leukemia resistant JQ1 Preclinical - Cell culture Actionable In a preclinical study, adult T cell leukemia cells expressing FBXW7 S462P treated with JQ1 demonstrated resistance in both short term and long term culture, and showed increased phosphorylation of Braf, Mek, and Erk, and increased expression of Stat3 and Myc (PMID: 32907612). 32907612
Unknown unknown adult T-cell leukemia not applicable Birabresib Preclinical - Patient cell culture Actionable In a preclinical study, patient-derived adult T cell leukemia cell lines with likely activation of Myc pathway signaling demonstrated decreased proliferation when treated with Birabresib (OTX015) in culture (PMID: 32907612). 32907612
FBXW7 W425R adult T-cell leukemia resistant JQ1 Preclinical - Cell culture Actionable In a preclinical study, adult T cell leukemia cells expressing FBXW7 W425R demonstrated resistance to treatment with JQ1 in culture (PMID: 32907612). 32907612
FBXW7 H468R adult T-cell leukemia resistant Birabresib Preclinical - Cell culture Actionable In a preclinical study, adult T cell leukemia cells expressing FBXW7 H468R were resistant to treatment with Birabresib (OTX015) in culture (PMID: 32907612). 32907612
FBXW7 S462P adult T-cell leukemia sensitive JQ1 + Ulixertinib Preclinical - Cell culture Actionable In a preclinical study, the combination treatment of JQ1 and Ulixertinib (BVD-523) resulted in greater decreased proliferation of adult T cell leukemia cells expressing FBXW7 S462P when compared to treatment with JQ1 alone in culture (PMID: 32907612). 32907612
Unknown unknown adult T-cell leukemia no benefit Dinaciclib Preclinical - Cell culture Actionable In a preclinical study, adult T cell leukemia cells were not sensitive to treatment with Dinaciclib (SCH 727965) in culture (PMID: 32907612). 32907612
Unknown unknown adult T-cell leukemia no benefit Sorafenib Preclinical - Cell culture Actionable In a preclinical study, adult T cell leukemia cells were not sensitive to treatment with Nexavar (sorafenib) in culture (PMID: 32907612). 32907612
FBXW7 H468R adult T-cell leukemia resistant JQ1 Preclinical - Cell culture Actionable In a preclinical study, adult T cell leukemia cells expressing FBXW7 H468R were resistant to treatment with JQ1 in culture (PMID: 32907612). 32907612
FBXW7 positive adult T-cell leukemia predicted - sensitive JQ1 Preclinical - Cell line xenograft Actionable In a preclinical study, adult T cell leukemia cells expressing FBXW7 in a mouse model demonstrated decreased tumor volume when treated with JQ1 (PMID: 32907612). 32907612